The efficacy of combination regime in helicobacter pylori eradication: A cross-sectional study from an experienced endoscopy center
Haseki Tip Bulteni, cilt.59, sa.5, ss.419-423, 2021 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 59 Sayı: 5
- Basım Tarihi: 2021
- Doi Numarası: 10.4274/haseki.galenos.2021.7273
- Dergi Adı: Haseki Tip Bulteni
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.419-423
- Anahtar Kelimeler: Helicobacter pylori, gastritis, antibiogram
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aim: The success of antibiotics used for eradication in the treatment of Helicobacter pylori (Hp)-positive gastritis is controversial. This study aims to evaluate the post-treatment eradication success/failure of Hp-positive gastritis cases, discuss antibiotic resistance, and what we can do additionally. Methods: The data of 1,471 patients who underwent upper gastrointestinal endoscopy between January 1 and December 31, 2019, were retrospectively evaluated through the hospital digital recording system. Of these, data of 126 patients who have been diagnosed with HP-positive gastritis and treated with a trio of clarithromycin, amoxicillin, and omeprazole were analyzed. Initial and control endoscopic pathologies and Hp-positivity were compared. Results: In the control of 126 patients, 87 (69%) patients had a normal endoscopic appearance, but only 46 (36.5%) patients were normal in the histopathological examinations of biopsies. Regardless of the severity, complete eradication of Hp was possible in 31 (24.6%) patients. There was no statistically significant difference in Hp detection rates after treatment (p=0.719 for 1+, p=0.583 for 2+, p for 3+)=0.980). Conclusion: In gastritis cases, Hp positivity continues despite the treatment, although the pathological severity changes. It is appropriate to discuss the effectiveness of routine treatments and to take culture/antibiogram, even bismuth including preparations to the forefront.